# SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

> **NCT05445154** · PHASE1,PHASE2 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Newly Diagnosed Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** SKLB1028 Dose Escalation

## Key facts

- **NCT ID:** NCT05445154
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-31
- **Primary completion:** 2024-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445154, "SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*